OGN Quote, Financials, Valuation and Earnings

Merck & has a net margin of 22.69% compared to Organon &'s net margin of 18.95%. Organon &'s return on equity of 25019.23% beat Merck &'s return on equity of 29.26%.

Organon & has a consensus price target of $22.50, signalling upside risk potential of 44.11%. On the other hand Merck & has an analysts' consensus of $130.34 which suggests that it could grow by 29.84%. Given that Organon & has higher upside potential than Merck &, analysts believe Organon & is more attractive than Merck &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Merck & has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.989%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 7.25%. Merck & offers a yield of 3.15% to investors and pays a quarterly dividend of $0.81 per share. Organon & pays 28.74% of its earnings as a dividend. Merck & pays out 2039.73% of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Merck &'s is not.

Organon & quarterly revenues are $1.6B, which are smaller than Merck & quarterly revenues of $16.7B. Organon &'s net income of $359M is lower than Merck &'s net income of $3.2B. Notably, Organon &'s price-to-earnings ratio is 3.06x while Merck &'s PE ratio is 20.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.62x versus 3.99x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 22.69% compared to Organon &'s net margin of -49.65%. Organon &'s return on equity of 25019.23% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Organon & has a consensus price target of $22.50, signalling upside risk potential of 44.11%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 503.14%. Given that NovaBay Pharmaceuticals has higher upside potential than Organon &, analysts believe NovaBay Pharmaceuticals is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 7.25%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 28.74% of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Organon &'s net income of $359M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Organon &'s price-to-earnings ratio is 3.06x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.62x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of 22.69% compared to Organon &'s net margin of -2357.27%. Organon &'s return on equity of 25019.23% beat Palatin Technologies's return on equity of --.

Organon & has a consensus price target of $22.50, signalling upside risk potential of 44.11%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than Organon &, analysts believe Palatin Technologies is more attractive than Organon &.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 7.25%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 28.74% of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Palatin Technologies quarterly revenues of $350K. Organon &'s net income of $359M is higher than Palatin Technologies's net income of -$7.8M. Notably, Organon &'s price-to-earnings ratio is 3.06x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.62x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of 22.69% compared to Organon &'s net margin of -788.06%. Organon &'s return on equity of 25019.23% beat Sage Therapeutics's return on equity of -48.2%.

Organon & has a consensus price target of $22.50, signalling upside risk potential of 44.11%. On the other hand Sage Therapeutics has an analysts' consensus of $8.00 which suggests that it could grow by 30.29%. Given that Organon & has higher upside potential than Sage Therapeutics, analysts believe Organon & is more attractive than Sage Therapeutics.

Organon & has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.909, suggesting its less volatile than the S&P 500 by 9.064%.

Organon & has a quarterly dividend of $0.28 per share corresponding to a yield of 7.25%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organon & pays 28.74% of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend. Organon &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Organon & quarterly revenues are $1.6B, which are larger than Sage Therapeutics quarterly revenues of $11.9M. Organon &'s net income of $359M is higher than Sage Therapeutics's net income of -$93.6M. Notably, Organon &'s price-to-earnings ratio is 3.06x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organon & is 0.62x versus 3.49x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.